OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd celebrates a major leap in the Spanish market with the 30th successful OncoSil™ device treatment for pancreatic cancer at Hospital HM Sanchinarro. The company reports a growing network of 16 Spanish sites engaged with the OncoSil™ device, indicating rapid market penetration and a positive outlook for further European expansion. OncoSil Medical’s commitment to revolutionizing pancreatic cancer treatment is reinforced by the device’s regulatory approvals in over 30 countries, including the entire European Union.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.
